JP2018532383A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018532383A5 JP2018532383A5 JP2018511264A JP2018511264A JP2018532383A5 JP 2018532383 A5 JP2018532383 A5 JP 2018532383A5 JP 2018511264 A JP2018511264 A JP 2018511264A JP 2018511264 A JP2018511264 A JP 2018511264A JP 2018532383 A5 JP2018532383 A5 JP 2018532383A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- sequence
- antibody
- monoclonal antibody
- cdr2
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562213140P | 2015-09-02 | 2015-09-02 | |
| US62/213,140 | 2015-09-02 | ||
| US201662314427P | 2016-03-29 | 2016-03-29 | |
| US62/314,427 | 2016-03-29 | ||
| PCT/IL2016/050952 WO2017037707A1 (en) | 2015-09-02 | 2016-09-01 | Antibodies specific to human t-cell immunoglobulin and itim domain (tigit) |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018532383A JP2018532383A (ja) | 2018-11-08 |
| JP2018532383A5 true JP2018532383A5 (https=) | 2019-10-03 |
| JP6861418B2 JP6861418B2 (ja) | 2021-04-28 |
Family
ID=57068160
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018511264A Active JP6861418B2 (ja) | 2015-09-02 | 2016-09-01 | ヒトｔ細胞免疫グロブリン及びｉｔｉｍドメイン（ｔｉｇｉｔ）に特異的な抗体 |
Country Status (6)
| Country | Link |
|---|---|
| US (2) | US10946095B2 (https=) |
| EP (1) | EP3344658B1 (https=) |
| JP (1) | JP6861418B2 (https=) |
| CN (1) | CN108137691B (https=) |
| ES (1) | ES2924071T3 (https=) |
| WO (1) | WO2017037707A1 (https=) |
Families Citing this family (64)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201403775D0 (en) | 2014-03-04 | 2014-04-16 | Kymab Ltd | Antibodies, uses & methods |
| TWI715587B (zh) | 2015-05-28 | 2021-01-11 | 美商安可美德藥物股份有限公司 | Ｔｉｇｉｔ結合劑和彼之用途 |
| PL3356413T3 (pl) | 2015-10-01 | 2022-04-19 | Potenza Therapeutics, Inc. | Białka anty-tigit wiążące antygen oraz sposoby ich zastosowania |
| US9567399B1 (en) | 2016-06-20 | 2017-02-14 | Kymab Limited | Antibodies and immunocytokines |
| KR102379464B1 (ko) | 2016-06-20 | 2022-03-29 | 키맵 리미티드 | 항-pd-l1 항체 |
| KR20260030924A (ko) | 2016-08-09 | 2026-03-06 | 키맵 리미티드 | 항-icos 항체 |
| EP3534947A1 (en) | 2016-11-03 | 2019-09-11 | Kymab Limited | Antibodies, combinations comprising antibodies, biomarkers, uses & methods |
| CN110662552A (zh) | 2016-11-30 | 2020-01-07 | 昂科梅德制药有限公司 | 包含tigit结合剂的癌症治疗方法 |
| JOP20190203A1 (ar) * | 2017-03-30 | 2019-09-03 | Potenza Therapeutics Inc | بروتينات رابطة لمولد ضد مضادة لـ tigit وطرق استخدامها |
| EP3615070A1 (en) | 2017-04-26 | 2020-03-04 | Bristol-Myers Squibb Company | Methods of antibody production that minimize disulfide bond reduction |
| RS64576B1 (sr) | 2017-05-01 | 2023-10-31 | Agenus Inc | Anti-tigit antitela i postupci njihove primene |
| CN110799213A (zh) | 2017-06-01 | 2020-02-14 | 康姆普根有限公司 | 三联组合抗体疗法 |
| WO2018229163A1 (en) | 2017-06-14 | 2018-12-20 | King's College London | Methods of activating v delta 2 negative gamma delta t cells |
| GB201709808D0 (en) | 2017-06-20 | 2017-08-02 | Kymab Ltd | Antibodies |
| US11512129B2 (en) | 2017-09-29 | 2022-11-29 | Jiangsu Hengrui Medicine Co., Ltd. | TIGIT antibody, antigen-binding fragment thereof, and medical use thereof |
| EP3728314A1 (en) | 2017-12-19 | 2020-10-28 | Kymab Limited | Bispecific antibody for icos and pd-l1 |
| GB201721338D0 (en) | 2017-12-19 | 2018-01-31 | Kymab Ltd | Anti-icos Antibodies |
| TW201930358A (zh) * | 2017-12-28 | 2019-08-01 | 大陸商南京傳奇生物科技有限公司 | 針對ｔｉｇｉｔ之單域抗體及其變異體 |
| EP3740507A4 (en) | 2018-01-15 | 2022-08-24 | Nanjing Legend Biotech Co., Ltd. | SINGLE DOMAIN ANTIBODIES AND VARIANTS THEREOF AGAINST PD-1 |
| CA3086936C (en) | 2018-02-06 | 2022-11-29 | I-Mab Biopharma Us Limited | Antibodies to t cell immunoreceptor with ig and itim domains (tigit) and uses thereof |
| KR102892725B1 (ko) | 2018-05-09 | 2025-12-01 | 이슘 리서치 디벨롭먼트 컴퍼니 오브 더 히브루 유니버시티 오브 예루살렘 엘티디. | 인간 넥틴4에 특이적인 항체 |
| CN110737397B (zh) * | 2018-07-20 | 2023-08-11 | 伊姆西Ip控股有限责任公司 | 用于管理存储系统的方法、设备和计算机程序产品 |
| KR20210040827A (ko) | 2018-07-25 | 2021-04-14 | 이노벤트 바이오로직스 (쑤저우) 컴퍼니, 리미티드 | 항 tigit 항체 및 그 용도 |
| JP2021534196A (ja) | 2018-08-23 | 2021-12-09 | シージェン インコーポレイテッド | 抗ｔｉｇｉｔ抗体 |
| CN113614109A (zh) | 2018-12-21 | 2021-11-05 | Ose免疫疗法公司 | 双功能抗pd-1/il-7分子 |
| US12545727B2 (en) | 2019-01-13 | 2026-02-10 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. | Antibodies specific to human Nectin-2 |
| WO2020165374A1 (en) | 2019-02-14 | 2020-08-20 | Ose Immunotherapeutics | Bifunctional molecule comprising il-15ra |
| CN111744013B (zh) * | 2019-03-29 | 2022-07-26 | 江苏恒瑞医药股份有限公司 | 抗tigit抗体联合pd-1抑制剂治疗疾病的方法和药物组合 |
| CN114269782B (zh) * | 2019-07-15 | 2023-12-29 | 上海君实生物医药科技股份有限公司 | 抗tigit抗体及其应用 |
| CN114641502B (zh) * | 2019-11-14 | 2023-11-14 | 上海药明生物技术有限公司 | 一种新的抗tigit抗体 |
| AU2020406083A1 (en) | 2019-12-17 | 2022-06-16 | Boehringer Ingelheim International Gmbh | Bifunctional molecules comprising an IL-7 variant |
| CN110818795B (zh) * | 2020-01-10 | 2020-04-24 | 上海复宏汉霖生物技术股份有限公司 | 抗tigit抗体和使用方法 |
| CA3176497A1 (en) | 2020-05-07 | 2021-11-11 | Fatima MECHTA-GRIGORIOU | Antxr1 as a biomarker of immunosuppressive fibroblast populations and its use for predicting response to immunotherapy |
| CN111995681B (zh) * | 2020-05-09 | 2022-03-08 | 华博生物医药技术（上海）有限公司 | 抗tigit的抗体、其制备方法和应用 |
| CN115916348A (zh) | 2020-06-18 | 2023-04-04 | 基因泰克公司 | 使用抗tigit抗体和pd-1轴结合拮抗剂的治疗 |
| TW202216778A (zh) | 2020-07-15 | 2022-05-01 | 美商安進公司 | Ｔｉｇｉｔ及ｃｄ１１２ｒ阻斷 |
| LT4269444T (lt) * | 2020-08-14 | 2024-09-25 | GammaDelta Therapeutics Limited | Daugiaspecifiniai anti-tcr kintamos delta 1 antikūnai |
| WO2022044010A1 (en) | 2020-08-26 | 2022-03-03 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. | Anti-t-cell immunoglobulin and itim domain (tigit) antibodies for the treatment of fungal infections |
| EP4226943A4 (en) * | 2020-10-09 | 2024-11-20 | Keio University | THERAPEUTIC AGENT FOR IMMUNE/INFLAMMATORY DISEASES |
| EP4238991A4 (en) * | 2020-11-23 | 2024-05-15 | Guangdong Fapon Biopharma Inc. | ANTI-TIGIT ANTIBODY OR ANTIGEN-BINDING FRAGMENT THEREOF |
| WO2022112198A1 (en) | 2020-11-24 | 2022-06-02 | Worldwide Innovative Network | Method to select the optimal immune checkpoint therapies |
| WO2022148781A1 (en) | 2021-01-05 | 2022-07-14 | Institut Curie | Combination of mcoln activators and immune checkpoint inhibitors |
| US20240270840A1 (en) | 2021-02-11 | 2024-08-15 | Nectin Therapeutics Ltd. | Antibodies against cd112r and uses thereof |
| AU2022253351A1 (en) | 2021-04-09 | 2023-10-12 | Boehringer Ingelheim International Gmbh | New scaffold for bifunctional molecules with improved properties |
| EP4320156A1 (en) | 2021-04-09 | 2024-02-14 | Ose Immunotherapeutics | Scaffold for bifunctioanl molecules comprising pd-1 or cd28 and sirp binding domains |
| AR125753A1 (es) | 2021-05-04 | 2023-08-09 | Agenus Inc | Anticuerpos anti-tigit, anticuerpos anti-cd96 y métodos de uso de estos |
| CN117916263B (zh) * | 2021-05-10 | 2025-04-25 | 美帝马布生物公司 | 抗tigit抗体及其用途 |
| CN118871463A (zh) | 2021-07-28 | 2024-10-29 | 基因泰克公司 | 用于治疗癌症的方法和组合物 |
| TW202321308A (zh) | 2021-09-30 | 2023-06-01 | 美商建南德克公司 | 使用抗ｔｉｇｉｔ抗體、抗ｃｄ３８抗體及ｐｄ—１軸結合拮抗劑治療血液癌症的方法 |
| EP4413366A4 (en) * | 2021-10-08 | 2025-09-10 | Tiberias Tech Hk Limited | TIBTECH METHODS AND COMPOSITIONS FOR THE DETECTION OF CDH17 |
| PE20251671A1 (es) | 2022-03-15 | 2025-06-30 | Compugen Ltd | Anticuerpos antagonistas de il-18bp y su uso en monoterapia y terapia de combinacion en el tratamiento del cancer |
| EP4537107A2 (en) | 2022-06-07 | 2025-04-16 | Genentech, Inc. | Method for determining the efficacy of a lung cancer treatment comprising an anti-pd-l1 antagonist and an anti-tigit antagonist antibody |
| WO2024003360A1 (en) | 2022-07-01 | 2024-01-04 | Institut Curie | Biomarkers and uses thereof for the treatment of neuroblastoma |
| WO2024028386A1 (en) | 2022-08-02 | 2024-02-08 | Ose Immunotherapeutics | Multifunctional molecule directed against cd28 |
| CN121358499A (zh) | 2023-03-30 | 2026-01-16 | Ose免疫疗法 | 靶向活化的免疫细胞以表达免疫细胞增强分子的基于脂质的纳米粒及其用途 |
| AU2024254671A1 (en) | 2023-03-30 | 2025-10-02 | Ose Immunotherapeutics | Method of synthesis of targeted lipid nanoparticle and uses thereof |
| TW202515608A (zh) | 2023-06-26 | 2025-04-16 | 以色列商坎布根有限公司 | Ｉｌ—１８ｂｐ拮抗抗體及其於癌症治療之單一療法及組合療法的用途 |
| WO2025068452A1 (en) | 2023-09-29 | 2025-04-03 | Negio Therapeutics | Guanfacine derivatives and their use in treating cancer |
| WO2025068461A1 (en) | 2023-09-29 | 2025-04-03 | Negio Therapeutics | Guanfacine derivatives and their use in treating cancer |
| WO2025132831A1 (en) | 2023-12-19 | 2025-06-26 | Universite D'aix-Marseille | N-heteroaryl derivatives and uses thereof for treating cancer |
| WO2025242835A1 (en) | 2024-05-22 | 2025-11-27 | Ose Immunotherapeutics | Molecules comprising masking linkers and uses thereof for the treatment of cancer |
| WO2025242836A1 (en) | 2024-05-22 | 2025-11-27 | Ose Immunotherapeutics | Molecules comprising masking linkers and uses thereof for the treatment of auto-immune or inflammatory diseases and disorders |
| WO2025262250A1 (en) | 2024-06-20 | 2025-12-26 | Negio Therapeutics | Guanfacine derivatives and their uses |
| WO2026068705A1 (en) | 2024-09-26 | 2026-04-02 | Ose Immunotherapeutics | Lipid-based nanoparticles comprising non-glycosylated fc domains and uses thereof |
Family Cites Families (43)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| DE3920358A1 (de) | 1989-06-22 | 1991-01-17 | Behringwerke Ag | Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung |
| DE69232137T2 (de) | 1991-11-25 | 2002-05-29 | Enzon Inc | Multivalente antigen-bindende proteine |
| HU215180B (hu) | 1992-01-23 | 1998-10-28 | Merck Patent Gmbh. | Eljárás monomer és dimer antitest-fragment fúziós fehérjék előállítására |
| US5869337A (en) | 1993-02-12 | 1999-02-09 | President And Fellows Of Harvard College | Regulated transcription of targeted genes and other biological events |
| JP3659261B2 (ja) | 1994-10-20 | 2005-06-15 | モルフォシス・アクチェンゲゼルシャフト | 組換体タンパク質の多機能性複合体への標的化ヘテロ結合 |
| GB9421405D0 (en) | 1994-10-21 | 1994-12-07 | Dow Chemical Co | Low voc laminating formulations |
| US5641870A (en) | 1995-04-20 | 1997-06-24 | Genentech, Inc. | Low pH hydrophobic interaction chromatography for antibody purification |
| CA2222055A1 (en) | 1995-05-23 | 1996-11-28 | Morphosys Gesellschaft Fur Proteinoptimierung Mbh | Multimeric proteins |
| WO1998023761A1 (en) | 1996-11-27 | 1998-06-04 | Genentech, Inc. | HUMANIZED ANTI-CD11a ANTIBODIES |
| WO1999063063A1 (en) | 1998-06-03 | 1999-12-09 | Northwestern University | Cellular proteins which mediate herpesvirus entry |
| US7193069B2 (en) | 2002-03-22 | 2007-03-20 | Research Association For Biotechnology | Full-length cDNA |
| US20040121370A1 (en) | 2002-09-11 | 2004-06-24 | Genentech, Inc. | Novel composition and methods for the treatment of immune related diseases |
| EP2116551A1 (en) | 2002-09-11 | 2009-11-11 | Genentech, Inc. | Compositions and methods for the treatment of immune related diseases |
| AU2003289899A1 (en) | 2002-12-05 | 2004-06-23 | Ludwig-Maximilians-Uni Versitat | Genetic switches for the detection of fusion proteins |
| EP1481993A1 (en) | 2003-05-28 | 2004-12-01 | Xerion Pharmaceuticals AG | Modulation of the poliovirus receptor function |
| PE20050928A1 (es) | 2003-11-21 | 2005-11-08 | Schering Corp | Combinaciones terapeuticas de anticuerpo anti-igfr1 |
| KR20060120161A (ko) | 2003-11-28 | 2006-11-24 | 아스트라제네카 아베 | 항체 |
| GT200500283A (es) | 2004-10-08 | 2006-05-08 | Inmunoterapia de desordenes autoinmunes | |
| EP3214095B1 (en) | 2005-05-12 | 2019-12-11 | ZymoGenetics, Inc. | Compositions and methods for modulating immune responses |
| MX2008004094A (es) | 2005-09-27 | 2009-02-27 | Efrat Biopolymers Ltd | Composiciones de polimero inyectables hidrofobicas, gelificantes. |
| MY162056A (en) | 2006-10-12 | 2017-05-31 | Univ Tokyo | Diagnosis and treatment of cancer using anti -ereg antibody |
| JP5142265B2 (ja) | 2007-05-28 | 2013-02-13 | 独立行政法人産業技術総合研究所 | 抗モータリン抗体のパラトープ及びエピトープ |
| WO2008146854A1 (ja) * | 2007-05-28 | 2008-12-04 | National Institute Of Advanced Industrial Science And Technology | 抗モータリン抗体のパラトープ及びエピトープ |
| EP2527366B1 (en) | 2007-06-12 | 2017-08-16 | AC Immune S.A. | Monoclonal anti beta amyloid antibody |
| KR101597842B1 (ko) * | 2008-01-11 | 2016-02-25 | 가부시키가이샤 진 테크노 사이언스 | 인간화된 항-알파9 인테그린 항체 및 그의 용도 |
| EP3208612B1 (en) | 2008-04-09 | 2019-09-18 | Genentech, Inc. | Compositions and methods for the treatment of immune related diseases |
| JP2010014691A (ja) | 2008-06-20 | 2010-01-21 | Igaku Seibutsugaku Kenkyusho:Kk | 腹水中のメソテリン及び／又は巨核球増強因子を検出するための方法、キット、試薬及び装置 |
| US8518405B2 (en) * | 2009-10-08 | 2013-08-27 | The University Of North Carolina At Charlotte | Tumor specific antibodies and uses therefor |
| US8256790B2 (en) | 2010-05-26 | 2012-09-04 | William Olen Fortner | Adjustable receiver hitch system |
| PL2800196T3 (pl) | 2011-12-27 | 2019-05-31 | Lg Chemical Ltd | Litowa bateria akumulatorowa i sposób jej wytwarzania |
| CN103073644B (zh) | 2012-12-31 | 2014-03-12 | 中国科学技术大学 | 特异性抗小鼠tigit的单克隆抗体及其制备方法、鉴定及应用 |
| GB201300052D0 (en) | 2013-01-03 | 2013-02-20 | Transimmune Ag | Method for obtaining immuno-suppressive dendritic cells |
| GB201300049D0 (en) | 2013-01-03 | 2013-02-20 | Transimmune Ag | Method for obtaining immuno-stimulatory dendritic cells |
| CA2916681A1 (en) * | 2013-07-16 | 2015-01-22 | Genentech, Inc. | Methods of treating cancer using pd-1 axis binding antagonists and tigit inhibitors |
| AU2015305754B2 (en) | 2014-08-19 | 2018-10-25 | Merck Sharp & Dohme Llc | Anti-tigit antibodies |
| US20170191034A1 (en) | 2014-09-04 | 2017-07-06 | Agency For Science Technology And Research | A method to up-regulate cancer stem cell markers for the generation of antigen specific cytotoxic effector t cells |
| EP3268012A4 (en) | 2015-03-12 | 2018-10-31 | Health Research, Inc. | Enrichment of cd16+ monocytes to improve dendritic cell vaccine quality |
| TWI715587B (zh) | 2015-05-28 | 2021-01-11 | 美商安可美德藥物股份有限公司 | Ｔｉｇｉｔ結合劑和彼之用途 |
| IL243461A0 (en) | 2016-01-05 | 2016-02-29 | Amir Avraham | Skin-augmenting surgical sutures |
-
2016
- 2016-09-01 CN CN201680051019.6A patent/CN108137691B/zh active Active
- 2016-09-01 EP EP16775866.3A patent/EP3344658B1/en active Active
- 2016-09-01 JP JP2018511264A patent/JP6861418B2/ja active Active
- 2016-09-01 WO PCT/IL2016/050952 patent/WO2017037707A1/en not_active Ceased
- 2016-09-01 ES ES16775866T patent/ES2924071T3/es active Active
- 2016-09-01 US US15/756,606 patent/US10946095B2/en active Active
-
2021
- 2021-02-05 US US17/168,451 patent/US12121579B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018532383A5 (https=) | ||
| RU2018134065A (ru) | Антитела, специфические к рецептору полиовируса (pvr) человека | |
| JP6518005B2 (ja) | Ｐｄ−ｌ１抗体 | |
| JP6767362B2 (ja) | リンパ球における阻害経路の中和 | |
| JP2019511212A5 (https=) | ||
| JP2017535257A5 (https=) | ||
| JP2021527431A5 (https=) | ||
| JP2018527919A5 (https=) | ||
| JP2019536470A5 (https=) | ||
| CN110536903A (zh) | 抗ox40抗体及其用途 | |
| CA3075969A1 (en) | Multispecific antibody comprising cd137 binding domain and pdl1 binding domain | |
| JP2019524693A5 (https=) | ||
| FI3332006T3 (fi) | Uusia anti-PD-L1-vasta-aineita | |
| IL261666B1 (en) | Binding proteins and methods of use thereof | |
| KR20170102167A (ko) | 항-pd-l1 항체 | |
| JP2018520657A5 (https=) | ||
| JP2013506428A5 (https=) | ||
| RU2017114341A (ru) | Антитела к pd-l1, связывающие pd-l1 собаки | |
| CA3075337A1 (en) | Antibodies targeting cd137 and methods of use thereof | |
| RU2016100892A (ru) | Антитела против tweakr и их применение | |
| FI3826667T3 (fi) | Claudin6 vasta-aineita ja menetelmiä syövän hoitamiseksi | |
| AU2020363041B2 (en) | Antibodies against the poliovirus receptor (PVR) and uses thereof | |
| EP3664843A1 (en) | Cd96-binding agents as immunomodulators | |
| JP2021533796A5 (https=) | ||
| JP2016501877A5 (https=) |